FOCUS Innovative Pharmaceuticals GmbH

FOCUS IP is specialised in intellectual property sourcing and due diligence activities. An established scouting team continuously values early discoverys stage license compounds from multiple sources such as academia, biotechs and pharma companies.

Based on internal criteria, selected pr-clinical compounds enter into a database. Following an expert due diligence covering clinical, market, IP and financial aspects, FOCUS IP selects candidates and recommends them to the development centres. The centers, in turn, can in-license these candidates for added-value development.

FOCUS is an independent drug development organisation with 120 employees, offering full-service Phase I to III clinical development packages or individual service modules. The headquarters are located in Neuss/Dusseldorf, Germany with affiliates in Heidelberg, Moscow, Belgrade, Dubai, Tokyo and Jakarta.
A team of highly qualified scientific experts at FOCUS provides customised fast-track and creative solutions from First-into-Man to clinical Proof of Concept.
FOCUS provides its services to the international pharmaceutical and biotechnology industry.

FOCUS Middle East & India (F-MEI) is a subsidiary of FOCUS Clinical Drug Development GmbH. F-MEI is dedicated to serving the development needs of pharmaceutical industry in India and the Middle East, focussing on taking existing products, NCEs and NBEs to registration in the EMEA region.

AVICENNA Pharma Development, due to its unique location and expertise, acts as the representative office for FOCUS Middle East & India.